LUCID DIAGNOSTICS INC

LUCDNASDAQ

🏆 #2772 by market capEarnings Aug 13US Equity

$0.96▲ $0.00 (+0.02%)

Live

1h—

24h▲ 0.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$183M

Small Cap

📈Revenue Growth (YoY)

+23.0%

Healthy

📊Gross Margin

-31.4%

Thin

💵FCF Margin

—

⚖️P/S Ratio

38.0x

Expensive

Otter Score

Fair

No chart data available for LUCD.

Trading Snapshot

Day Range: $0.96 – $0.97
52-Week Range: $0.86 – $1.63
Volume: $2.24B
Avg Volume: $2.37B
Shares Outstanding: 190.8M
Next Earnings: Sep 12, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: 38.0x
EPS (TTM): $-0.36
Dividend Yield: —

Why Investors Own LUCD

✓High-growth profile — revenue up +5.5% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5M▲ +6.8% YoY

Gross Margin (TTM)

50.5%▲ +2.8% YoY

Operating Income (TTM)

$1M▲ +6.8% YoY

Free Cash Flow (TTM)

$1M▲ +6.8% YoY

About LUCID DIAGNOSTICS INC

Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.

🦦